SEC-sourced researchBeta
VYGR
Voyager Therapeutics, Inc.
Company comparison ↗
Data passport
- CIK
- 0001640266
- Exchange
- Nasdaq
- Business activity
- — · SIC 2836
- Financial inputs
- 6/6
- Filing date
- Mar 9, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 250,008,000.0000 | Mar 9, 2026 |
| December 2024 | 80,001,000.0000 | Mar 9, 2026 |
| December 2025 | 40,374,000.0000 | Mar 9, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 40,374,000.0000 | -119,721,000.0000 | -132,467,000.0000 | 252,281,000.0000 | 56,200,000.0000 | Mar 9, 2026 |
| December 2024 | 80,001,000.0000 | -65,002,000.0000 | -15,310,000.0000 | 393,050,000.0000 | 93,290,000.0000 | Mar 9, 2026 |
| December 2023 | 250,008,000.0000 | 132,330,000.0000 | 77,919,000.0000 | — | — | Mar 9, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $40.37M | December 2025 | Mar 9, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $80M | December 2024 | Mar 9, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$119.72M | December 2025 | Mar 9, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$132.47M | December 2025 | Mar 9, 2026 | 10-K |
| Total assetsAssets | $252.28M | December 2025 | Mar 9, 2026 | 10-K |
| Total liabilitiesLiabilities | $56.2M | December 2025 | Mar 9, 2026 | 10-K |